In this study, we quantify HER2 release from positive mammary tumor cells to demonstrate that histotripsy treatment could trigger the release of HER2 in vitro in cultured cells as well as ex vivo in a murine tumor model in a dose-dependent manner. Here, ERBB2 is linked to neoplasm.